Tepotinib

Unassigned

New Medicines

Advanced non-small cell lung cancer (NSCLC) with mesenchymal–epithelial transition (MET) exon 14 skipping mutations or MET amplification

Information

New molecular entity
Merck (or Merck KGaA)
Merck (or Merck KGaA)

Development and Regulatory status

None
Phase II Clinical Trials
Phase II Clinical Trials

Category

A small-molecule inhibitor of proto-oncogene protein c-met. Tepotinib inhibits both hepatocyte growth factor-dependent and -independent c-Met activation in low nanomolar concentrations
MET-mutations are clinically unique molecular subtypes of NSCLC, with MET exon 14 (METex14) alteration conferring oncogene addiction in ~3-4% of NSCLC. There are currently no approved therapies specifically targeting METex14 and/or c-Met amplification [1].
Advanced non-small cell lung cancer (NSCLC) with mesenchymal–epithelial transition (MET) exon 14 skipping mutations or MET amplification
Oral